Tirzepatide
Also known as Mounjaro, Zepbound, LY3298176
Tirzepatide is a once-weekly peptide that activates both the GIP and GLP-1 receptors, producing average weight loss of about 20 percent at the top dose in trials. It is sold as Mounjaro for diabetes and Zepbound for weight management and sleep apnea.
Reviewed by the amino101 editorial team. , first published .
Quick start
What people commonly do. Not a prescription.- Typical dose
- 2.5 mg (starting dose)
- How often
- once weekly
- Where
- Subcutaneous, abdomen, thigh or upper arm, rotate sites
- Timing
- same day each week, any time, with or without food
- Effects timeline
- appetite drops within the first 1 to 2 weeks, weight loss builds from about week 4, plateau around 12 to 18 months
- Storage
- fridge 2 to 8 C once mixed, use within 4 weeks
- Cycle length
- ongoing, increase by 2.5 mg every 4 weeks as tolerated
- Break between
- none planned; taper gradually if stopping, regain after withdrawal was substantial in trials
2.5 mg is the tolerance step. The maintenance doses studied are 5, 10 and 15 mg weekly; plenty of people hold at 5 or 7.5 mg because that is where appetite control and side effects balance out for them.
Overview
Tirzepatide is a single 39 amino acid peptide built on the GIP hormone backbone and tuned to activate both the GIP and GLP-1 receptors. Eli Lilly developed it with a fatty diacid side chain for albumin binding, which gives it a half-life of about five days and once-weekly dosing. It reached the market as Mounjaro for type 2 diabetes in 2022 and as Zepbound for chronic weight management in late 2023, later adding an indication for obstructive sleep apnea in people with obesity.
The headline numbers come from SURMOUNT-1: adults with obesity but not diabetes lost an average of about 15, 19.5 and 20.9 percent of body weight at the 5, 10 and 15 mg doses over 72 weeks, against about 3 percent on placebo. In the head-to-head SURMOUNT-5 trial against semaglutide 2.4 mg, tirzepatide 15 mg produced roughly 20 percent loss versus about 14 percent, which makes it the strongest approved option as of now.
As with semaglutide, the vials sold through research suppliers are not the branded product. Lilly does sell single-dose Zepbound vials through its own direct-to-consumer channel in the US, and those are legitimate. Grey-market lyophilized tirzepatide is a separate thing with no guaranteed purity, and underdosed or mislabeled vials are a documented problem in that market. If you are going to inject it, batch testing is worth the cost.
How it works
Tirzepatide hits two incretin receptors at once. The GLP-1 side does what semaglutide does: it boosts glucose-dependent insulin release, slows gastric emptying and dampens hunger signaling in the brain. The GIP side is less well understood but appears to add to appetite suppression, improve how fat tissue handles lipids, and may soften some of the nausea that GLP-1 activation alone produces. The molecule is actually biased toward the GIP receptor and is a weaker GLP-1 agonist than semaglutide molecule for molecule, yet the combination produces larger weight loss, which is the main argument that dual agonism is doing something real rather than just being a stronger GLP-1 drug.
Where the research stands
Chronic weight managementStrong evidence
- Obesity without diabetes. SURMOUNT-1 RCT, about 21 percent mean loss at 15 mg over 72 weeks.
- Head to head against semaglutide. SURMOUNT-5 RCT, roughly 20 versus 14 percent loss at 72 weeks.
- Overweight with type 2 diabetes. SURMOUNT-2 RCT, about 13 to 15 percent loss.
Type 2 diabetesStrong evidence
- Glucose control. SURPASS program RCTs, HbA1c reductions of about 2 points, larger than semaglutide 1 mg in SURPASS-2.
- Cardiovascular safety. SURPASS-CVOT RCT showed cardiovascular outcomes at least as good as dulaglutide.
Obstructive sleep apneaStrong evidence
- Moderate to severe OSA with obesity. SURMOUNT-OSA RCTs cut the apnea-hypopnea index by roughly 25 to 30 events per hour, leading to an FDA indication.
Diabetes preventionModerate evidence
- Prediabetes progression. SURMOUNT-1 three-year extension showed over 90 percent lower progression to type 2 diabetes while on treatment.
Heart failure with preserved ejection fractionModerate evidence
- HFpEF with obesity. SUMMIT RCT reduced heart failure events and improved symptoms.
- human RCTUp to 20.9 percent mean weight loss at 15 mg weekly over 72 weeks in adults with obesity (SURMOUNT-1).
- human RCTBeat semaglutide 2.4 mg head to head, about 20 percent versus 14 percent weight loss at 72 weeks (SURMOUNT-5).
- human RCTGreater HbA1c reduction than semaglutide 1 mg in type 2 diabetes (SURPASS-2).
- clinical (approved drug)Cut the apnea-hypopnea index by roughly 25 to 30 events per hour in obesity-related sleep apnea (SURMOUNT-OSA), leading to an FDA indication.
- human RCTReduced progression from prediabetes to type 2 diabetes by over 90 percent across three years of treatment (SURMOUNT-1 extension).
Rodent and in vitro mean no human data for that finding. Human pilot means small, often uncontrolled. Human RCT means randomized and controlled. Clinical means an approved drug with regulatory data.
Levels over time
Modeled from the half-life. Illustrative, not measured.Dosing every 7 d with a half-life of 4.9 d means each dose lands on top of what is left from the last one. Levels climb to about 1.6 times a single dose before settling, roughly 19.5 d in.
Five days is long enough for once-weekly dosing to hold steady levels, and it means each 2.5 mg step takes about 3 weeks to reach its full effect, which is why the label waits 4 weeks between increases.
Tirzepatide dosage and protocols
Not cycled. The label is a stepwise titration of 2.5 mg every 4 weeks, and most people settle at whatever step controls appetite. If a step causes persistent nausea, stay there another month before moving up. Stopping is done as a taper because the withdrawal trial showed most of the lost weight returning within a year.
| Goal | Dose | Frequency | Route |
|---|---|---|---|
| Weeks 1 to 4, tolerance | 2.5 mg | once weekly | Subcutaneous |
| Weeks 5 to 8 | 5 mg | once weekly | Subcutaneous |
| Weeks 9 to 12 | 7.5 mg | once weekly | Subcutaneous |
| Weeks 13 to 16 | 10 mg | once weekly | Subcutaneous |
| Week 17 onward, if still needed | 12.5 to 15 mg | once weekly | Subcutaneous |
Food and time of day do not affect the injection. Evening dosing is common so the roughest hours land during sleep. Keep the weekday consistent; a missed dose can be taken within 4 days, otherwise skip to the next scheduled one. Anyone on oral contraceptives should use a backup method for 4 weeks after starting and after each increase, since absorption drops during titration.
Start 2.5 mg weekly for 4 weeks, then increase by 2.5 mg every 4 weeks as tolerated. 5, 10 and 15 mg are the maintenance doses studied; plenty of people hold at 5 or 7.5 mg.
Dose calculator
U-100 insulin syringeUnits are a volume on the syringe, not an amount of peptide. Concentration changes every time you change the water volume. The standalone calculator explains the math.
| Vial | Suggested water | Concentration | Low dose draw |
|---|---|---|---|
| 10 mg | 1 mL | 10 mg/mL | 25 units |
| 15 mg | 1.5 mL | 10 mg/mL | 25 units |
| 30 mg | 3 mL | 10 mg/mL | 25 units |
| 60 mg | 6 mL | 10 mg/mL | 25 units |
How to reconstitute Tirzepatide
- 1
Wash your hands and wipe the work surface. Swab both vial stoppers with alcohol and let them dry.
- 2
Pick the water volume with the calculator above and write it on the vial. The concentration means nothing without it.
- 3
Draw the bacteriostatic water into a mixing syringe.
- 4
Insert at an angle and let the water run down the inside wall. Never squirt it straight onto the powder.
- 5
Swirl gently or leave it to dissolve. Do not shake.
- 6
Label with the date and water volume. Store in the fridge at 2 to 8 C and use within about 4 weeks.
- 7
Unmixed vials keep for months in the fridge and longer in the freezer, sealed and out of light.
- Full walkthrough with syringe reading and site rotation: reconstitution guide.
- ✓White, fluffy cake
Lyophilized powder should look like a small white puck or fluffy cake at the bottom of the vial. That is a proper freeze-dry.
- ✓Clear after mixing
Once dissolved the solution should be water-clear with nothing floating in it.
- !Slight clumping
Small clumps that dissolve with gentle swirling are fine. Shipping compacts powder.
- ✕Collapsed or melted
Powder stuck to the sides, glassy, or shrunken means it got hot in transit. Contact the vendor.
- ✕Cloudy or particles
Persistent cloudiness or visible particles after mixing means degraded or contaminated product. Do not use it.
- Week 1 to 4
Appetite noticeably lower even at 2.5 mg for many people, mild nausea, early fullness. A few pounds may come off.
- Week 4 to 12
Loss of about 1 to 2 pounds a week as the dose climbs, food noise fades, side effects flare briefly after each step.
- Month 3 to 6
Consistent loss at maintenance dose, GI effects settle, most people are 10 percent or more down.
- Month 6 to 18
Loss slows toward a plateau near 15 to 20 percent of starting weight depending on dose. Protein and lifting decide how much of it is fat.
Interactions and stacking
Cagrilintidecompatible
Community stack borrowed from CagriSema to add amylin satiety; no trial data for this specific pairing, so escalate the cagrilintide slowly.
Semaglutideavoid
Both activate GLP-1 receptors and both last a week; stacking adds nausea, not results.
Retatrutideavoid
Overlapping GIP and GLP-1 activity with no reason to combine and no data.
Insulin and sulfonylureascaution
Hypoglycemia becomes a real risk in combination; the other drug usually needs a dose reduction.
Oral contraceptivescaution
Slowed gastric emptying lowers pill absorption for the first weeks on each dose, so the label advises a backup method.
Oral medications with a narrow margincaution
Same absorption issue applies to warfarin, levothyroxine and similar drugs during titration.
Ipamorelin and other ghrelin mimeticscompatible
No known conflict, though ghrelin mimetics raise hunger and can partly offset appetite suppression.
MOTS-ccompatible
Community pairing to support exercise capacity during a cut; untested together.
Safety
- ▲Nausea and reduced appetite, worst right after each dose increase
- ▲Diarrhea or constipation
- ▲Burping, reflux and indigestion
- ▲Fatigue during the first weeks of each step
- ▲Injection site reactions
- ▲Hair shedding a few months into rapid loss
- ▲GI effects (nausea, vomiting, diarrhea, constipation) are the main reason people quit. Slow escalation and smaller meals fix most of it.
- ▲Same rodent thyroid C-cell tumor warning as other GLP-1 drugs. Avoid with medullary thyroid cancer or MEN2 history.
- ▲Hypoglycemia is a real risk when combined with insulin or sulfonylureas. Not an issue for most non-diabetic users.
- ▲Rapid loss can mean hair shedding, gallstones and lean mass loss. Protein, lifting and a sane rate of loss help.
- ▲Delayed gastric emptying matters for anesthesia and can change absorption of oral medications, including birth control pills during titration.
- ■Severe or persistent abdominal pain, especially radiating to the back, a possible sign of pancreatitis
- ■Right upper abdominal pain, fever or yellowing skin, which can mean gallbladder disease
- ■Vomiting or diarrhea severe enough to cause dehydration or dizziness on standing
- ■A neck lump, hoarseness or trouble swallowing
- ■Signs of low blood sugar if combined with insulin or a sulfonylurea
Community poll
Self-reported by visitors. Not clinical evidence.Tirzepatide: frequently asked
Tirzepatide or semaglutide?
Tirzepatide produced more weight loss in the head-to-head trial, about 20 percent versus 14 percent at 72 weeks, and many users report milder nausea. Semaglutide has the cardiovascular outcomes data and a longer safety track record. Cost and availability often decide it in practice.
Why does the nausea come back after each dose increase?
Each step up raises the blood level and the gut has to re-adapt to slower emptying. It usually settles within a week or two. If it does not, staying at the current dose for another month before increasing is the standard fix.
Do I have to reach 15 mg?
No. The trials show a dose-response, but 5 mg still produced 15 percent average loss. The right dose is the lowest one that keeps appetite under control with tolerable side effects.
What is the difference between a Zepbound vial and research tirzepatide?
Zepbound vials are Lilly's own product, sold through their direct channel, already in solution and lot tested. Research tirzepatide is lyophilized powder from an unregulated supplier that you reconstitute yourself. The molecule is meant to be the same; the quality assurance is not.
Does it work for people who are not diabetic?
Yes, SURMOUNT-1 was run specifically in people without diabetes and produced the largest weight loss numbers. Blood sugar effects in non-diabetics are minimal because insulin release is glucose-dependent.
References
- Tirzepatide once weekly for the treatment of obesity (SURMOUNT-1). New England Journal of Medicine, 2022
- Tirzepatide versus semaglutide once weekly in patients with type 2 diabetes (SURPASS-2). New England Journal of Medicine, 2021
- Tirzepatide versus semaglutide for weight loss in adults with obesity without diabetes (SURMOUNT-5). New England Journal of Medicine, 2025
- Tirzepatide for the treatment of obstructive sleep apnea and obesity (SURMOUNT-OSA). New England Journal of Medicine, 2024